1-10 of 10
Sonal Patel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, Anshu Kuriakose, Shivakumar Bhadravathi Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, Shruthi Rao, Madhukara AR, Vinita Tiwari, Bhavna Alke, Prashantha Kumar MV, Meena Shri, Chaitrali Dhamne, Sonal Patel, Pinky Sharma, Sankar Periyasamy, Jaya Bhatnagar, Moni Abraham Kuriakose, Ram Bhupal Reddy, Amritha Suresh, Suma Sreenivas, Nagaraja Govindappa, Praveen Reddy Moole, Usha Bughani, Seng-Lai Tan, Pradip Nair
Journal: Cancer Research
Cancer Res (2023) 83 (11): 1883–1904.
https://doi.org/10.1158/0008-5472.CAN-21-4425
Published: 02 June 2023
View article titled, BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
Open the PDF for BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth in another window
Includes: Supplementary data
Journal Articles

Abstract LB155: Combination of IGF-1R targeted alpha therapy with checkpoint inhibitors results in synergistic efficacy in a syngeneic colorectal tumor model

Sonal Patel, Natalie Grinshtein, Ryan Simms, Meiduo Hu, John Valliant, Eric Burak
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): LB155.
https://doi.org/10.1158/1538-7445.AM2021-LB155
Published: 01 July 2021
View article titled, Abstract LB155: Combination of IGF-1R targeted alpha therapy with checkpoint inhibitors results in synergistic efficacy in a syngeneic colorectal tumor model
Journal Articles

Abstract 3359: Translating preclinical PK/PD tumor volume modeling data to predict AMG172 PK and dose-escalation scheme in FIH.

Nelson L. Jumbe, William Fanslow, Sonal Patel, Benny Amore, Marc Retter, Vincent Chow
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3359.
https://doi.org/10.1158/1538-7445.AM2013-3359
Published: 15 April 2013
View article titled, Abstract 3359: Translating preclinical PK/PD tumor volume modeling data to predict AMG172 PK and dose-escalation scheme in FIH.
Journal Articles

Abstract 4635: Development of monoclonal antibodies against the GPCR CXCR4 and the ion channel Hv1 using virus-like particles

Joseph Rucker, Riley Payne, Manu Mabila, Sonal Patel, Moniquetta Hall, Sharon Willis, Benjamin J. Doranz
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 4635.
https://doi.org/10.1158/1538-7445.AM2012-4635
Published: 15 April 2012
View article titled, Abstract 4635: Development of monoclonal antibodies against the GPCR CXCR4 and the ion channel Hv1 using virus-like particles
Journal Articles

Abstract 2787: Discovery of GDC-0980, a selective PI3K/mTOR inhibitor in clinical trials

Daniel P. Sutherlin, Marcia Belvin, Linda Bao, Leanne Berry, Megan Berry, Georgette Castanedo, Kyle Edgar, Adrian Folkes, Lori Friedman, Tim Heffron, Sonal Patel, Alan Olivero, John Lesnick, Cristina Lewis, James Marsters, Jim Nonomiya, Jodie Pang, Wei Wei Prior, Laurent Salphati, Deepak Sampath, Vickie Tsui, Jeff Wallin, BinQing Wei, Christian Weismann, Bing-Yan Zhu
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2787.
https://doi.org/10.1158/1538-7445.AM2011-2787
Published: 15 April 2011
View article titled, Abstract 2787: Discovery of GDC-0980, a selective PI3K/mTOR inhibitor in clinical trials
Journal Articles

Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling

Naseer Qayum, Ruth J. Muschel, Jae Hong Im, Lukxmi Balathasan, Cameron J. Koch, Sonal Patel, W. Gillies McKenna, Eric J. Bernhard
Journal: Cancer Research
Cancer Res (2009) 69 (15): 6347–6354.
https://doi.org/10.1158/0008-5472.CAN-09-0657
Published: 29 July 2009
View article titled, Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling
Open the PDF for Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling in another window
Includes: Supplementary data
Journal Articles

Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity

Remko Prevo, Eric Deutsch, Oliver Sampson, Julie Diplexcito, Keith Cengel, Jane Harper, Peter O'Neill, W. Gillies McKenna, Sonal Patel, Eric J. Bernhard
Journal: Cancer Research
Cancer Res (2008) 68 (14): 5915–5923.
https://doi.org/10.1158/0008-5472.CAN-08-0757
Published: 15 July 2008
View article titled, Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity
Open the PDF for Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity in another window
Includes: Supplementary data
Journal Articles

The discovery of GDC-0941: A potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Adrian Folkes, Stewart Baker, Irina Chuckowree, Suzanne Eccles, Angela Hayes, Timothy Hancox, Mohammed Latif, Alan Olivero, Sonal Patel, Giles Pergl-Wilson, Florence Raynaud, Anthony Robson, Nahid Saghir, Sukhjit Sohal, Nan Chi Wan, Christian Weissman, Paul Workman, Marketa Zvelebil, Stephen Shuttleworth
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-146.
Published: 01 May 2008
View article titled, The discovery of GDC-0941: A potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Journal Articles

The novel potent PI3 Kinase inhibitors, PI-540 and PI-620: Activity in vitro and in vivo

Sonal Patel, Frederico Rojo, Letitia Lensun, Giles Pergl-Wilson, Nahid Saghir, Alexander Zhyvoloup, Anthony Robson, Florence Raynaud, Adrian Folkes, Paul Workman, Stephen Shuttleworth, Wendy Alderton
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-192.
Published: 01 May 2008
View article titled, The novel potent PI3 Kinase inhibitors, PI-540 and PI-620: Activity <em>in vitro</em> and <em>in vivo </em>
Journal Articles

Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

Florence I. Raynaud, Suzanne Eccles, Paul A. Clarke, Angela Hayes, Bernard Nutley, Sonia Alix, Alan Henley, Francesca Di-Stefano, Zahida Ahmad, Sandrine Guillard, Lynn M. Bjerke, Lloyd Kelland, Melanie Valenti, Lisa Patterson, Sharon Gowan, Alexis de Haven Brandon, Masahiko Hayakawa, Hiroyuki Kaizawa, Tomonubu Koizumi, Takahide Ohishi, Sonal Patel, Nahid Saghir, Peter Parker, Mike Waterfield, Paul Workman
Journal: Cancer Research
Cancer Res (2007) 67 (12): 5840–5850.
https://doi.org/10.1158/0008-5472.CAN-06-4615
Published: 15 June 2007
View article titled, Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Open the PDF for Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases in another window
Includes: Supplementary data